Artelo Biosciences Inc Stock

$9.72

3.09% yesterday

Nasdaq, Aug 12, 10:00 pm CET

ISIN

US04301G2012

Symbol

ARTL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Artelo Biosciences Inc Stock price

$9.72

-100.98 91.22% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

-0.31 3.09%

ISIN

US04301G2012

Symbol

ARTL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$7.1m

Enterprise Value

$6.3m

Net debt

positive

Cash

$750.0k

Shares outstanding

550.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

10.9

Financial Health

Equity Ratio

60.8%

Return on Equity

-344.1%

ROCE

-1,374.4%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | -

EBIT

$-9.9m | $-10.7m

Net Income

$-9.7m | $-4.9m

Free Cash Flow

$-7.0m

EPS

$-17.8

FCF per Share

$-12.7

Short interest

4.4%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Artelo Biosciences Inc forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Artelo Biosciences Inc forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Artelo Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.03 4.03	5% 5% -
- Research and Development Expense	5.87 5.87	2% 2% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-9.90 -9.90	3% 3% -
Net Profit	-9.71 -9.71	1% 1% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Artelo Biosciences Inc Stock News

Neutral

GlobeNewsWire

●

one day ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, d...

Neutral

GlobeNewsWire

●

9 days ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo's digital asset treasury Artelo's Board approves authorization to expand Company's SOL treasury management strategy over time SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc....

Neutral

GlobeNewsWire

●

12 days ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway

More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office	United States
CEO	Gregory Gorgas
Employees	6
Founded	2011
Website	artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now